NCT01291914 - Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

March 31, 2012

Conditions

Osteoarthritis, Knee

Interventions

DRUG

FX005

Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)

DRUG

Placebo 1 (Carrier)

Single intra-articular injection

DRUG

Placebo 2 (Diluent)

Single intra-articular injection

Trial Locations (13)

Unknown

Graz

Vienna

Penticton

Newmarket

Toronto

Windsor

Sainte-Foy

Santiago de Compostela

Santander

A Coruña

Barcelona

Seville

Southampton